OCAT post Young1ne: "Well well are these folks starting to realize that 4 years of data on late stage patients, on a disease that is unmet, and a phase I/II that was successfully completed across the globe with 0 side effects and a huge improvement in VA considering the fact, is the next biggest thing? One year $35 is a very conservative but can as well be a realistic price target. I been saying that as soon as the 12 week readout comes out of the first few AMD patients things are going to really get enticing. I also believe it is not going to take too long for these big jumps to occur.
"SPA soon"
"Phase II soon"
More coverage
More marketing of Ocata
But more importantly these patients will not hold their tongue when they can see again. This time, and boy do I really mean this time around Ocata will hit every news outlet with these patients. I know for a fact BP, whoever is the smart one is making offers and possibly waiting for this first read out. I cannot believe REGN is over $500. Ocata potential is GARGANTUAN
Ooops I forgot we have pre-clinical data and that JV by end of year."
